Figure 2
From: A circulating miRNA assay as a first-line test for prostate cancer screening
Circulating miR-106a/miR-130b and miR-106a/miR-223 ratios predict the presence of localised prostate cancer. (A) Relative expression levels are shown as 2−ΔCt (see Materials and methods). Both miRNA ratios were significantly higher (one-tailed Wilcoxon rank-sum test) in PCa patients compared with biopsy-negative patients (P=6.97 × 10−6 for miR-106a/miR-130b; P=8.5 × 10−5 for miR-106a/miR-223). (B) Receiver operating characteristic (ROC) curves generated for univariate (red and blue traces) and bivariate (black trace) logistic regression models against the ROC curve of PSA (green trace). The miRNA ratios were better than PSA for discriminating PCa from BIO− samples. Areas under ROC curves (AUC) are shown in parentheses. (C) Proposed miRNA-based diagnostic flowchart for PCa diagnosis.
